In line with these observations, in approximately 14% of IDH-mutant glioma patients, alterations in known cancer driver genes, such as PI3KCA/KRAS mutations in IDH/CIC mutant gliomas and PDGFRA/MET amplification in IDH/TP53 gliomas occurred [146]. This evidence concerns the gene IDH2 and cancer.